期刊文献+

胸腔细管引流同时口服强的松治疗结核性大量胸腔积液的疗效分析 被引量:1

Analysis of Curative Effect Combination Therapy of Glucocorticoid with Drainage-microtube for Serious Typical Tuberculous Symptom in Associatin with Tuberculous Pleural Effusion
下载PDF
导出
摘要 目的:探讨胸腔细管持续引流同时口服强的松治疗结核性大量胸腔积液并临床结核中毒症状较重患者的疗效。方法:对住院确诊的46例单纯性结核性大量胸腔积液并临床结核中毒症状较重患者随机分为治疗组和对照组。治疗组在规则抗结核基础上行胸腔细管持续引流并同时口服强的松,直至胸液消失后拔管;对照组在规则抗结核基础上予常规胸穿抽液,直至胸液消失。观察临床结核中毒症状、胸液压迫症状及胸液消失时间;胸膜粘连及肥厚、包裹性胸腔积液的发生率。结果:与对照组比较,治疗组临床结核中毒症状、胸液压迫症状及胸液的消失时间均显著缩短;胸膜粘连及肥厚、包裹性胸腔积液的发生率明显较低。结论:胸腔细管持续引流同时口服强的松是治疗结核性大量胸腔积液并临床结核中毒症状较重患者的有效治疗方法,具有良好的安全性及较强的可行性,疗效确切,值得临床推广应用。 Objective: To evaluate effect of combination therapy of glucocorticoid with drainage-microtube for treating patients with serious typical tuberculous symptom in association with tuberculous pleural effusion.Methods:46 patients with serious typical tuberculous symptom in association with tuberculous pleural effusion were randomly divided into treatment group and control group.The patients of treatment group were treated by glucocorticoid drainage-microtube.Aspiration for pleural effusion in the control group.Regular antituberculosis treatment was conducted for all patients.Results:The disappearance times of tuberculotic toxic symptoms and pleural effusion in the treatment group were signifcantly shorter than that in control group.The occurance rates of pleural thickning,pleural adhesion and pleural effusion in treatment group was less than that in control group.Conclusion:Glucocortocoid plus drainage-microtube therapy is a safe,convenient,and effective method for serious typical tuberculous symptoms in association with tuberculous pleural effusion.
出处 《医学理论与实践》 2005年第7期768-770,共3页 The Journal of Medical Theory and Practice
关键词 结核 大量胸腔积液 胸腔细管引流 强的松 Tuberculosis,Pleural effusion,Glucocorticoid
  • 相关文献

参考文献3

二级参考文献20

  • 1辛茜,孙春田.结核性渗出性胸膜炎发生胸膜肥厚因素的探讨[J].新疆医学,1994,24(1):14-15. 被引量:3
  • 2马向东.浆膜结核[M].石家庄:河北科学技术出版社,1991.1-8.
  • 3[3]Tillett WS, Sherry.Effect in patients of streotococcal fibrinolysin (streptokinase)and streptococcal desoxyribonuclease on fibrinous,purulent and sanguinous exudations. J Clin Invest,1949,28(1):173~186.
  • 4[4]Bergh NP,Ekroth R,Larson S,et al.Intrapleural streptokinase in the treatment of empyema and hemothorsx.Scand J Cardiovase Surg,1997,11(2):265~268.
  • 5[5]Aye RW,Froese DP,Hill LD.Use of purified streptokinase in the treatment of empyema and hemothorax.Am J Surg ,1991,161(3):560~562.
  • 6[6]Davies RJ,Traill Z C,Gleeson F V.et al. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection.Thorax,1997,52(3):416~421.
  • 7[7]Nyat Koui Chin,Tow K Lim.Controlled trial of intrapleural streptikinase in the treatment of pleural empyema and complicated paraneumonic effusions.Chest, 1997,111(2):275~279.
  • 8[8]Carlos Jerjes Sanchez,et al. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema.Chest,1996,109(9):1514~1519.
  • 9[9]Moulton JS,Moore Pt,Menane Ra.Treatment of loculated pleural effusions with transtheter intradcavitary urikinase.ARJ,1989,153(4):941~945.
  • 10[10]Thomas T R, Intrapleural fibrinolysis in the management of empyema thoracis.Chest,1996,110(1):102~106.

共引文献200

同被引文献6

引证文献1

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部